- Home
- TENX vs RDHL Comparison
TENX vs RDHL Comparison
Compare TENX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- RDHL
- Stock Information
- Founded
- TENX 1967
- RDHL 2009
- Country
- TENX United States
- RDHL Israel
- Employees
- TENX N/A
- RDHL N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- RDHL Health Care
- Exchange
- TENX Nasdaq
- RDHL Nasdaq
- Market Cap
- TENX 19.5M
- RDHL 8.6M
- IPO Year
- TENX N/A
- RDHL N/A
- Fundamental
- Price
- TENX $5.61
- RDHL $6.50
- Analyst Decision
- TENX Strong Buy
- RDHL
- Analyst Count
- TENX 4
- RDHL 0
- Target Price
- TENX $20.67
- RDHL N/A
- AVG Volume (30 Days)
- TENX 67.4K
- RDHL 21.3K
- Earning Date
- TENX 11-13-2024
- RDHL 12-27-2024
- Dividend Yield
- TENX N/A
- RDHL N/A
- EPS Growth
- TENX N/A
- RDHL N/A
- EPS
- TENX N/A
- RDHL N/A
- Revenue
- TENX N/A
- RDHL $3,707,000.00
- Revenue This Year
- TENX N/A
- RDHL $224.90
- Revenue Next Year
- TENX N/A
- RDHL $82.69
- P/E Ratio
- TENX N/A
- RDHL N/A
- Revenue Growth
- TENX N/A
- RDHL N/A
- 52 Week Low
- TENX $2.77
- RDHL $6.00
- 52 Week High
- TENX $27.36
- RDHL $40.50
- Technical
- Relative Strength Index (RSI)
- TENX 54.30
- RDHL 38.21
- Support Level
- TENX $5.70
- RDHL $6.00
- Resistance Level
- TENX $6.01
- RDHL $7.30
- Average True Range (ATR)
- TENX 0.47
- RDHL 0.51
- MACD
- TENX -0.08
- RDHL -0.09
- Stochastic Oscillator
- TENX 12.15
- RDHL 21.10
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.